Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23095604 | 0.81 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1CA12CA1CA2 | |
| SCHEMBL147071 | 0.81 | FFAR1 (0.65) | ALDH1A1LMNAHTTHSD17B10PKM | |
| SCHEMBL11442961 | 0.81 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1LMNAHTTHSD17B10 | |
| SCHEMBL7016205 | 0.80 | LMNA (0.47) | SMN1; SMN2ALDH1A1LMNAHTTHSD17B10 | |
| SCHEMBL19604046 | 0.79 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1LMNAHTTHSD17B10 | |
| SCHEMBL13113137 | 0.79 | PKM (0.51) | ALDH1A1LMNAHTTHSD17B10PKM | |
| SCHEMBL3735701 | 0.79 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1LMNAHTTHSD17B10 | |
| SCHEMBL7421131 | 0.79 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1LMNAHTTHSD17B10 | |
| Hydrochloric Acid SCHEMBL1376065 | 0.79 | FFAR1 (0.63) | ALDH1A1LMNAHTTHSD17B10PKM | |
| SCHEMBL15563329 | 0.79 | ALDH1A1 (0.57) | SMN1; SMN2ALDH1A1LMNAHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0525057-B1 | ANTIMICROBIAL QUINOLONYL LACTAMS | PROCTER & GAMBLE PHARMA (US) | 2000-06-14 | — | — | EP | claimed |
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| WO-2008140214-A1 | USE OF AMINOTHIOPHENE DERIVATIVE FOR PREVENTING OR TREATING ISCHEMIC DISEASES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-11-20 | — | — | WO | disclosed |
| US-20080090863-A1 | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| EP-1363925-B8 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2007-04-25 | — | — | EP | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-4891427-A | BACTERICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-01-02 | — | — | US | disclosed |
| US-4876251-A | ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-10-24 | — | — | US | disclosed |
| US-4851422-A | Antibiotic 2-(3-oxo-2-isoxazolidinyl)-5-oxo-2-tetrahydrofuran-carboxylates | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-07-25 | — | — | US | disclosed |
| EP-0271829-A2 | Delta-hydroxy-beta-lysine derivatives and their production | Takeda Chemical Industries, Ltd. (JP) | 1988-06-22 | — | — | EP | disclosed |
| EP-0250096-A1 | Isoxazolone derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-12-23 | — | — | EP | disclosed |
| EP-0249909-A1 | Tricyclic penam compounds, their production and their use | Takeda Chemical Industries, Ltd. (JP) | 1987-12-23 | — | — | EP | disclosed |
| EP-0219923-A1 | Antibiotic derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-04-29 | — | — | EP | disclosed |
| EP-0191989-A1 | Antibiotic isoxazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-08-27 | — | — | EP | disclosed |
| EP-0051234-B1 | A PROCESS FOR THE PRODUCTION OF A 2-AZETIDINONE DERIVATIVE | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1985-03-13 | — | — | EP | disclosed |
| EP-0051234-A1 | A process for the production of a 2-azetidinone derivative | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1982-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | SMN1; SMN2 3467/4885ALDH1A1 1605/4885CA12 3056/4885 |
| US-20080090863-A1 | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor | MCHR1, GPR119, MCHR2 | SMN1; SMN2 1609/4885ALDH1A1 1549/4885CA12 4408/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | SMN1; SMN2 3467/4885ALDH1A1 1605/4885CA12 3056/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | SMN1; SMN2 3554/4885ALDH1A1 2549/4885CA12 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.